Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy

Neuropharmacology

Volumn 45, Issue 4, 2003, Pages 493-503

  Moo Puc, Rosa E ^a   Góngora Alfaro, José L ^a,b   Alvarez Cervera, Fernando J ^a   Pineda, Juan C ^a   Arankowsky Sandoval, Gloria ^a   Heredia López, Francisco ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b NONE   (Mexico)

Author keywords

Adenosine A2A; Atropine; Caudate putamen; Parkinson; Striatum; Trihexyphenidyl

Indexed keywords

ATROPINE; CAFFEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; MUSCARINIC RECEPTOR BLOCKING AGENT; TRIHEXYPHENIDYL;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICHOLINERGIC EFFECT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CROSS TOLERANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG POTENTIATION; EXPERIMENTAL MODEL; LATENT PERIOD; LOW DRUG DOSE; MALE; MEDICAL ASSESSMENT; NONHUMAN; PARKINSON DISEASE; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

EID: 0037619882     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00202-8     Document Type: Article

References (44)

1. Bédard M.A., Pillon B., Dubois B., Duchesne N., Masson H., Agid Y. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cogn. 40:1999;289-313.
2. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 23:2000;120-126.
3. Cauli O., Morelli M. Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D1 and D2 receptor agonists. Psychopharmacology. 162:2002;246-254.
4. 2 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 98:2001;1970-1975.
5. Chou D.T., Khan S., Forde J., Hirsh K.R. Caffeine tolerance: behavioral, electrophysiological and neurochemical evidence. Life Sci. 36:1985;2347-2358.
6. Da Cunha C., Angelucci M.E., Canteras N.S., Wonnacott S., Takahashi R.N. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell. Mol. Neurobiol. 22:2002;227-237.
7. Daly J.W., Shi D., Nikodijević O., Jacobson K.A. The role of adenosine receptors in the central action of caffeine. Gupta B.S., Gupta U. Caffeine and Behavior. 1999;1-16 CRC Press, Boca Raton, FL, USA.
8. De Boer P., Abercrombie E.D. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J. Pharmacol. Exp. Ther. 277:1996;775-783.
9. De Boer P., Abercrombie E.D., Heeringa M., Westerink B.H.C. Differential effect of systemic administration of bromocriptine and L-DOPA on the release of acetylcholine from striatum of intact and 6-HODA-treated rats. Brain Res. 608:1993;198-203.
10. 3-like muscarinic autoreceptor regulates the in vivo release of acetylcholine in rat striatum. Eur. J. Pharmacol. 179:1990;167-172.
11. 2A receptor knockout mice are partially protected against drug-induced catalepsy. NeuroReport. 12:2001;983-986.
12. Ezrin-Waters C., Muller P., Seeman P. Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs. Can. J. Physiol. Pharmacol. 54:1976;516-519.
13. Fahn S., Burke R., Stern Y. Antimuscarinic drugs in the treatment of movement disorders. Prog. Brain Res. 84:1990;389-397.
14. Ferré S., Popoli P., Giménez-Llort L., Rimondini R., Müller C.E., Strömberg I., Ögren S.O., Fuxe K. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat. Disord. 7:2001;235-241.
15. Finn I.B., Holtzman S.G. Pharmacologic specificity of tolerance to caffeine-induced stimulation of locomotor activity. Psychopharmacology. 93:1987;428-434.
16. Fredholm B.B., Bättig K., Holmén J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51:1999;83-133.
17. 1 receptor interactions in the basal ganglia. Brain Res. Rev. 26:1998;258-273.
18. Galarraga E., Hernández-López S., Reyes A., Miranda I., Bermudez-Rattoni F., Vilchis C., Bargas J. Cholinergic modulation of neostriatal output: a functional antagonism between different types of muscarinic receptors. J. Neurosci. 19:1999;3629-3638.
19. Góngora-Alfaro, J.L., Moo-Puc, R.E., Alvarez-Cervera, F., Pineda-Cortés, J.C., Arankowsky-Sandoval, G., 2002. Caffeine acts synergically with anticholinergics to inhibit haloperidol-induced catalepsy. Abstract Viewer/Itinerary Planner Online. Society for Neuroscience, Washington, DC. Program No. 165.3.
20. 2A receptor antagonist. Eur. J. Pharmacol. 406:2000;345-354.
21. 2A receptors in the caudate-putamen. NeuroReport. 9:1998;1803-1806.
22. Holtzman S.G. Complete, reversible, drug-specific tolerance to stimulation of locomotor activity by caffeine. Life Sci. 33:1983;779-787.
23. Holtzman S.G., Mante S., Minneman K.P. Role of adenosine receptors in caffeine tolerance. J. Pharmacol. Exp. Ther. 256:1991;62-68.
24. 3H]acetylcholine release. J. Neurochem. 62:1994;960-966.
25. Kirkpatrick K.A., Richardson P.J. Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes. Br. J. Pharmacol. 110:1993;949-954.
26. 2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 66:1996;1882-1888.
27. Lau C.E., Falk J.L. Tolerance to oral and IP caffeine: locomotor activity and pharmacokinetics. Pharmacol. Biochem. Behav. 48:1994;337-344.
28. Lau C., Falk J. Dose-dependent surmountability of locomotor activity in caffeine tolerance. Pharmacol. Biochem. Behav. 52:1995;139-143.
29. Malec D. Haloperidol-induced catalepsy is influenced by adenosine receptor antagonists. Pol. J. Pharmacol. 49:1997;323-327.
30. 2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 328:1997;135-141.
31. Guide for the Care and Use of Laboratory Animals. 1996;National Academy Press, Washington, DC.
32. Nehlig A., Boyet S. Dose-response study of caffeine effects on cerebral functional activity with a specific focus on dependence. Brain Res. 858:2000;71-77.
33. Nishiyama K., Mizuno T., Sakuta M., Kurisaki H. Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv. Neurol. 60:1993;479-483.
34. Pondal M., Del Ser T., Bermejo F. Anticholinergic therapy and dementia in patients with Parkinson's disease. J. Neurol. 243:1996;543-546.
35. Riedel W., Hogervorst E., Leboux R., Verhey F., van Praag H., Jolles J. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology. 122:1995;158-168.
36. Richardson P.J., Dixon A.K., Lee K., Bell M.I., Cox P.J., Williams R., Pinnock R.D., Freeman T.C. Correlating physiology with gene expression in striatal cholinergic neurones. J. Neurochem. 74:2000;839-846.
37. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 18:1997;338-344.
38. Sanberg P.R., Martinez R., Shytle R.D., Cahill D.W. The catalepsy test: is a standardized method possible? Sanberg P.R., Ossenkoop K.-P., Kavaliers M. Motor Activity and Movement Disorders. 1996;197-211 Humana Press, Totowa, NJ.
39. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 147:1999;90-95.
40. Stoof J.C., Drukarch B., De Boer P., Westerink B.H.C., Groenewegen H.J. Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience. 47:1992;755-770.
41. 2A receptors. Prog. Neurobiol. 59:1999;355-396.
42. Van Spaendonck K.P., Berger H.J., Horstink M.W., Buytenhuijs E.L., Cools A.R. Impaired cognitive shifting in Parkinsonian patients on anticholinergic therapy. Neuropsychologia. 31:1993;407-411.
43. 2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology. 111:1993;383-388.
44. 2 receptors. J. Neurosci. 20:2000;5949-5957.